DaVita (NYSE:DVA) Given New $228.00 Price Target at TD Cowen

Key Points

• TD Cowen raised DaVita’s price target to $228 from $220 and maintained a “buy” rating, implying approximately 25.8% upside from the reported $181.29 share price.
• Analyst sentiment is broadly positive but mixed: four analysts rate DaVita a buy and three rate it a hold, producing a “Moderate Buy” consensus and an average price target of $237.
• DaVita exceeded quarterly expectations, reporting $3.82 in EPS versus a $3.57 estimate and $3.58 billion in revenue, up 4.6% year over year. Institutional ownership stands at 90.12%, including a major new stake from Berkshire Hathaway.

DaVita (NYSE:DVA - Get Free Report) had its price objective hoisted by investment analysts at TD Cowen from $220.00 to $228.00 in a note issued to investors on Monday, Benzinga reports. The firm presently has a "buy" rating on the stock. TD Cowen's price objective suggests a potential upside of 25.77% from the company's current price.

A number of other brokerages have also commented on DVA. Weiss Ratings raised DaVita from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Friday, October 9th. Zacks Research lowered shares of DaVita from a "strong-buy" rating to a "hold" rating in a report on Monday, July 6th. UBS Group reissued a "buy" rating and set a $287.00 target price on shares of DaVita in a report on Monday. Deutsche Bank Aktiengesellschaft restated a "buy" rating and issued a $265.00 price target on shares of DaVita in a research report on Wednesday, August 5th. Finally, Wall Street Zen downgraded shares of DaVita from a "buy" rating to a "hold" rating in a research note on Saturday. Four analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $237.00.

DaVita Price Performance

DVA stock traded down $6.21 during midday trading on Monday, reaching $181.29. The company had a trading volume of 266,040 shares, compared to its average volume of 894,088. The company has a market capitalization of $11.40 billion, a price-to-earnings ratio of 13.30, a price-to-earnings-growth ratio of 0.48 and a beta of 0.87. The stock has a 50 day moving average price of $181.36 and a 200-day moving average price of $176.50. DaVita has a 1-year low of $101.00 and a 1-year high of $247.49.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The company reported $3.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.57 by $0.25. The company had revenue of $3.58 billion for the quarter, compared to analyst estimates of $3.52 billion. DaVita had a negative return on equity of 225.93% and a net margin of 6.49%. The company's revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter last year, the company posted $2.51 EPS. As a group, research analysts anticipate that DaVita will post 14.74 earnings per share for the current year.

Institutional Trading of DaVita

Several institutional investors have recently added to or reduced their stakes in the stock. Berkshire Hathaway Inc bought a new stake in shares of DaVita in the 2nd quarter valued at $6,425,269,000. BlackRock Inc. bought a new stake in DaVita during the second quarter valued at $547,520,000. Bank of America Corp DE bought a new stake in DaVita during the second quarter valued at $145,057,000. Bank of New York Mellon Corp acquired a new stake in DaVita during the 2nd quarter worth about $101,127,000. Finally, Deutsche Bank AG acquired a new stake in DaVita during the 2nd quarter worth about $46,356,000. 90.12% of the stock is currently owned by institutional investors.

DaVita Company Profile

DaVita Inc NYSE: DVA is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.